{"id":286251,"date":"2021-08-29T21:00:00","date_gmt":"2021-08-30T02:00:00","guid":{"rendered":"http:\/\/my.dev.vanderbilt.edu\/richardpeek\/?guid=1514d1c96d46e18adf7cd24506b15174"},"modified":"2021-08-31T23:00:00","modified_gmt":"2021-09-01T04:00:00","slug":"775a-risankizumab-induction-therapy-in-patients-with-moderate-to-severe-crohns-disease-with-intolerance-or-inadequate-response-to-conventional-andor-biologic-therapy-results-from-the-phase","status":"publish","type":"post","link":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/2021\/08\/775a-risankizumab-induction-therapy-in-patients-with-moderate-to-severe-crohns-disease-with-intolerance-or-inadequate-response-to-conventional-andor-biologic-therapy-results-from-the-phase\/","title":{"rendered":"775a Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn\u2019s Disease with Intolerance or Inadequate Response to Conventional and\/or Biologic Therapy: Results from the Phase 3 ADVANCE Study"},"content":{"rendered":"<p>Risankizumab (RZB) is a monoclonal antibody against interleukin-23, a key cytokine in the pathogenesis of inflammatory bowel disease. Phase 2 studies have shown efficacy and safety of RZB in patients with Crohn&#8217;s disease (CD). Here we report results of ADVANCE (NCT03105128), a double-blind randomized phase 3 study evaluating efficacy and safety of RZB as induction therapy in patients with moderate to severe CD.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Risankizumab (RZB) is a monoclonal antibody against interleukin-23, a key cytokine in the pathogenesis of inflammatory bowel disease. Phase 2 studies have shown efficacy and safety of RZB in patients with Crohn&#8217;s disease (CD). Here we report results of&#8230; <a href=\"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/2021\/08\/775a-risankizumab-induction-therapy-in-patients-with-moderate-to-severe-crohns-disease-with-intolerance-or-inadequate-response-to-conventional-andor-biologic-therapy-results-from-the-phase\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":5910,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-286251","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/posts\/286251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/users\/5910"}],"replies":[{"embeddable":true,"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/comments?post=286251"}],"version-history":[{"count":119,"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/posts\/286251\/revisions"}],"predecessor-version":[{"id":286587,"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/posts\/286251\/revisions\/286587"}],"wp:attachment":[{"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/media?parent=286251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/categories?post=286251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/my.dev.vanderbilt.edu\/richardpeek\/wp-json\/wp\/v2\/tags?post=286251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}